StenoCare reported FY 2025 net sales of DKK 7.0 million and EBITDA of DKK -1.7 million, with net financial items of DKK -0.4 million, result per share of DKK -0.06 and solidity of 75%. In Q4 2025, net sales were DKK 2.6 million (up 107%), EBITDA was DKK 0.01 million, net financial items were DKK 0.05 million, result per share was DKK 0.00 and solidity was 75%. Management said the company delivered three consecutive quarters of positive EBITDA in 2025 and noted FY 2025 EBITDA includes DKK -0.8 million related to exiting the Danish cultivation facility and a January 2025 share issue. The company highlighted the November 2025 acquisition of CannGros ApS, adding DKK 4–6 million in annual revenue potential and supporting its 2026 break-even goal, and said FY 2025 net sales including CannGros for the ownership period from Nov. 17, 2025 were DKK 7.3 million. After the period, StenoCare announced a January 2026 partnership with WEECO Pharma to launch a new Astrum oil product in Germany planned to reach patients in Feb 2026, and a February 2026 strategic partnership and distribution setup to secure a first-mover position in France.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260225:BIT:6596:0) on February 26, 2026, and is solely responsible for the information contained therein.